Comparative Pharmacology
Head-to-head clinical analysis: HYDROMOX R versus LOPRESSOR HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROMOX R versus LOPRESSOR HCT.
HYDROMOX R vs LOPRESSOR HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
LOPRESSOR HCT is a combination of metoprolol tartrate (a beta-1 selective adrenergic receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Metoprolol reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing plasma volume.
Oral, 50 mg once daily, increased to 100 mg once daily if needed.
1-2 tablets (each containing metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg) orally once daily, maximum 4 tablets daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Metoprolol: 3-7 hours (terminal half-life); extensive metabolizers (CYP2D6) ~3-4 h, poor metabolizers ~7-8 h. Hydrochlorothiazide: 6-15 hours (terminal half-life).
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30% as unchanged drug and metabolites.
Metoprolol: <5% unchanged in urine; rest metabolized in liver (CYP2D6) and excreted renally as metabolites. Hydrochlorothiazide: >95% excreted unchanged in urine within 24 hours via tubular secretion.
Category C
Category C
Thiazide Diuretic Combination
Beta-Blocker/Thiazide Diuretic Combination